Comparison of NT-ProBNP Changes in Heart Failure Patients Following ACEI vs ARB Therapy

Intan Kusuma Dewi, Halla Hisan Hartoto, Shofiatul Fajriyah

Abstract


NT-proBNP is a specific biomarker synthesized directly by the ventricular heart muscle under conditions of stretching or stress. The decrease in NT-proBNP levels correlates with clinical improvement in heart failure; a decrease exceeding the biological variation (>25%) indicates a good therapeutic response. Comparing effectiveness of ACEi and ARB therapies in outpatient heart failure patients in reducing NT-proBNP levels. This prospective study involved outpatient heart failure patients receiving ACEi or ARB therapy. Blood samples were taken at baseline and after two months of therapy from patients who met the inclusion criteria. The study included 27 subjects meeting inclusion criteria (13 ACEi group and 14 ARB group). The percentage change in NT-proBNP for ACEi was 29.47% (1.85 – 67.82) and for ARB was 40.53% (9.11-131.02), which was not statistically significant (p = 0.308). There were no significant changes in kidney function assessed by eGFR from baseline to post-therapy (p >0.05). The effectiveness of ACEi therapy compared to ARB in reducing NT-proBNP levels over two months was not significantly different.

Keywords


NT-proBNP: Heart Failure; Angiotensin Receptor Blocker (ARB); Angiotensin Converting Enzyme Inhibitor (ACEi)

Full Text:

PDF

References


Badan Penelitian dan Pengembangan Kesehatan, Laporan Nasional Riskesdas 2018. Jakarta: Lembaga Penerbit Badan Penelitian dan Pengembangan Kesehatan, 2020. Accessed: Jul. 04, 2024. [Online]. Available: https://repository.badankebijakan.kemkes.go.id/id/eprint/3514/

R. E. Uli, R. P. U. Satyana, E. Zomer, D. Magliano, D. Liew, and Z. Ademi, "Health and productivity burden of coronary heart disease in the working Indonesian population using life-table modelling" BMJ Open, vol. 10, no. 9, p. e039221, Sep. 2020, doi: 10.1136/bmjopen-2020-039221.

P. A. Heidenreich et al., "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines" Circulation, vol. 145, no. 18, May 2022, doi: 10.1161/CIR.0000000000001063.

R. H. G. Schwinger, "Pathophysiology of heart failure" Cardiovasc Diagn Ther, vol. 11, no. 1, pp. 263-276, Feb. 2021, doi: 10.21037/cdt-20-302.

H.-P. Brunner-La Rocca and S. Sanders-van Wijk, "Natriuretic Peptides in Chronic Heart Failure" Card Fail Rev, vol. 5, no. 1, pp. 44-49, Feb. 2019, doi: 10.15420/cfr.2018.26.1.

K. Kuwahara, "The natriuretic peptide system in heart failure: Diagnostic and therapeutic implications" Pharmacology & Therapeutics, vol. 227, p. 107863, Nov. 2021, doi: 10.1016/j.pharmthera.2021.107863.

P. A. Heidenreich et al., "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure" Journal of the American College of Cardiology, vol. 79, no. 17, pp. e263-e421, May 2022, doi: 10.1016/j.jacc.2021.12.012.

F. Ricci, A. Di Castelnuovo, G. Savarese, P. Perrone Filardi, and R. De Caterina, "ACE-inhibitors versus angiotensin receptor blockers for prevention of events in cardiovascular patients without heart failure "” A network meta-analysis" International Journal of Cardiology, vol. 217, pp. 128-134, Aug. 2016, doi: 10.1016/j.ijcard.2016.04.132.

T. Ohtsubo et al., "Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers in hypertensive patients with myocardial infarction or heart failure: a systematic review and meta-analysis" Hypertens Res, vol. 42, no. 5, pp. 641-649, May 2019, doi: 10.1038/s41440-018-0167-5.

L. Frankenstein et al., "The prognostic value of individual NT-proBNP values in chronic heart failure does not change with advancing age" Heart, vol. 95, no. 10, pp. 825-829, May 2009, doi: 10.1136/hrt.2008.158626.

S. Masson et al., "Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial)" J Am Coll Cardiol, vol. 52, no. 12, pp. 997-1003, Sep. 2008, doi: 10.1016/j.jacc.2008.04.069.

R. Latini et al., "Effects of Valsartan on Circulating Brain Natriuretic Peptide and Norepinephrine in Symptomatic Chronic Heart Failure: The Valsartan Heart Failure Trial (Val-HeFT)" Circulation, vol. 106, no. 19, pp. 2454-2458, Nov. 2002, doi: 10.1161/01.CIR.0000036747.68104.AC.

A. L. Bui, T. B. Horwich, and G. C. Fonarow, "Epidemiology and risk profile of heart failure" Nat Rev Cardiol, vol. 8, no. 1, pp. 30-41, Jan. 2011, doi: 10.1038/nrcardio.2010.165.

J. McMurray and S. Stewart, "Epidemiology, aetiology, and prognosis of heart failure" Heart, vol. 83, no. 5, pp. 596-602, May 2000, doi: 10.1136/heart.83.5.596.

M. J. Domanski, M. R. Mehra, M. A. Pfeffer, and E. Braunwald, Eds., Oxford textbook of advanced heart failure and cardiac transplantation. in Oxford textbooks in cardiology. Oxford: Oxford University Press, 2016.

A. Malik, D. Brito, S. Vaqar, and L. Chhabra, "Congestive Heart Failure" in StatPearls, Treasure Island (FL): StatPearls Publishing, 2024. Accessed: Jun. 27, 2024. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK430873/

R. D. Shahjehan and B. S. Bhutta, "Coronary Artery Disease" in StatPearls, Treasure Island (FL): StatPearls Publishing, 2024. Accessed: Jun. 27, 2024. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK564304/

Z. Blázquez"Bermejo et al., "Dose of furosemide before admission predicts diuretic efficiency and long"term prognosis in acute heart failure" ESC Heart Fail, vol. 9, no. 1, pp. 656-666, Nov. 2021, doi: 10.1002/ehf2.13696.

M. Miyata et al., "Comparative study of therapeutic effects of short- and long-acting loop diuretics in outpatients with chronic heart failure (COLD-CHF)" Journal of Cardiology, vol. 59, no. 3, pp. 352-358, May 2012, doi: 10.1016/j.jjcc.2011.12.007.

P. Tao, T. Zhitao, and L. Jiming, "A retrospective study on the short-term effect of high-dose spironolactone (80 mg/d) on chronic congestive heart failure" Medicine (Baltimore), vol. 100, no. 5, p. e23188, Feb. 2021, doi: 10.1097/MD.0000000000023188.

J. P. Ferreira et al., "Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial" European Journal of Heart Failure, vol. 24, no. 5, pp. 771-778, 2022, doi: 10.1002/ejhf.2455.

P. Srisawasdi, S. Vanavanan, C. Charoenpanichkit, and M. H. Kroll, "The Effect of Renal Dysfunction on BNP, NT-proBNP, and Their Ratio" American Journal of Clinical Pathology, vol. 133, no. 1, pp. 14-23, Jan. 2010, doi: 10.1309/AJCP60HTPGIGFCNK.

H. Ma et al., "The Diagnostic Accuracy of N-Terminal Pro-B-Type Natriuretic Peptide and Soluble ST2 for Heart Failure in Chronic Kidney Disease Patients: A Comparative Analysis" Med Sci Monit, vol. 29, pp. e940641-1-e940641-8, Sep. 2023, doi: 10.12659/MSM.940641.

I. K. Dewi, M. Aminuddin, and B. S. Zulkarnain, "ANALYSIS OF CHANGE IN NT-proBNP AFTER ANGIOTENSIN RECEPTOR BLOCKER (ARB) THERAPY IN PATIENT WITH HEART FAILURE" FMI, vol. 52, no. 4, p. 305, Aug. 2017, doi: 10.20473/fmi.v52i4.5480.

H. H. Hartoto, B. S. Zulkarnain, and M. Aminuddin, "ANALYSIS OF CHANGES IN THE SERUM LEVEL NT-proBNP AFTER ACE INHIBITORS THERAPY IN PATIENTS WITH HEART FAILURE" FMI, vol. 52, no. 3, p. 193, Aug. 2017, doi: 10.20473/fmi.v52i3.5451.

D. Pascual-Figal et al., "NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study" JACC: Heart Failure, vol. 8, no. 10, pp. 822-833, Oct. 2020, doi: 10.1016/j.jchf.2020.05.012.

A. J. Shrimpton, S. L. M. Walker, and G. L. Ackland, "Angiotensin converting enzyme inhibitors and angiotensin receptor blockers" BJA Educ, vol. 20, no. 11, pp. 362-367, Nov. 2020, doi: 10.1016/j.bjae.2020.07.004.

R. Troughton, G. Michael Felker, and J. L. Januzzi, "Natriuretic peptide-guided heart failure management" Eur Heart J, vol. 35, no. 1, pp. 16-24, Jan. 2014, doi: 10.1093/eurheartj/eht463.

J. L. Januzzi, "The role of natriuretic peptide testing in guiding chronic heart failure management: review of available data and recommendations for use" Arch Cardiovasc Dis, vol. 105, no. 1, pp. 40-50, Jan. 2012, doi: 10.1016/j.acvd.2011.10.007.

R. Chen et al., "Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study" Hypertension, vol. 78, no. 3, pp. 591-603, Sep. 2021, doi: 10.1161/HYPERTENSIONAHA.120.16667.

J.-G. Lee et al., "Impact of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers on clinical outcomes in hypertensive patients with acute myocardial infarction" PLoS One, vol. 18, no. 3, p. e0281460, Mar. 2023, doi: 10.1371/journal.pone.0281460.

"Comparative Effectiveness of ACE Inhibitors and ARBs" American College of Cardiology. Accessed: Jun. 27, 2024. [Online]. Available: https://www.acc.org/Latest-in-Cardiology/Journal-Scans/2021/08/03/19/47/http%3a%2f%2fwww.acc.org%2fLatest-in-Cardiology%2fJournal-Scans%2f2021%2f08%2f03%2f19%2f47%2fComparative-Effectiveness-of-ACE-Inhibitors-and-ARBs




DOI: https://doi.org/10.37311/ijpe.v4i2.26472

Refbacks



Copyright (c) 2024 Intan Kusuma Dewi

Creative Commons License
Indonesian Journal of Pharmaceutical Education is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.